Dan Yue1, Xun Sun2. 1. a Department of Laboratory Medicine , ShengJing Hospital of China Medical University , Shenyang , China. 2. b Department of Immunology , China Medical University , Shenyang , China.
Abstract
BACKGROUND: Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of the anti-tumor effect of ixazomib in colorectal cancer (CRC) cells remains unclear. METHODS: MTS and flow cytometry were performed to determine the effect of ixazomib on CRC cells. Western blotting and real-time RT-PCR were performed to detect ixazomib-induced DR5 upregulation. ChIP was performed to detect CHOP binding to DR5 promoter. Finally, xenograft experiments were carried out to measure the antitumor effect of ixazomib in vivo. RESULTS: In this study, we revealed the mechanism by which ixazomib inhibits the growth of CRC cells. Our findings indicated that ixazomib treatment induces CHOP-dependent DR5 induction, irrespective of p53 status. Furthermore, DR5 is necessary for ixazomib-mediated apoptosis. Ixazomib also synergized with TRAIL to induce marked apoptosis via DR5 in CRC cells. CONCLUSIONS: Our findings further suggested that ixazomib sensitizes TRAIL/death receptor signaling pathway-targeted CRC and suggested that DR5 induction could be a valuable indicator of ixazomib sensitivity.
BACKGROUND:Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of the anti-tumor effect of ixazomib in colorectal cancer (CRC) cells remains unclear. METHODS: MTS and flow cytometry were performed to determine the effect of ixazomib on CRC cells. Western blotting and real-time RT-PCR were performed to detect ixazomib-induced DR5 upregulation. ChIP was performed to detect CHOP binding to DR5 promoter. Finally, xenograft experiments were carried out to measure the antitumor effect of ixazomib in vivo. RESULTS: In this study, we revealed the mechanism by which ixazomib inhibits the growth of CRC cells. Our findings indicated that ixazomib treatment induces CHOP-dependent DR5 induction, irrespective of p53 status. Furthermore, DR5 is necessary for ixazomib-mediated apoptosis. Ixazomib also synergized with TRAIL to induce marked apoptosis via DR5 in CRC cells. CONCLUSIONS: Our findings further suggested that ixazomib sensitizes TRAIL/death receptor signaling pathway-targeted CRC and suggested that DR5 induction could be a valuable indicator of ixazomib sensitivity.
Entities:
Keywords:
CHOP; Ixazomib; TRAIL; death receptor 5; extrinsic apoptotic pathway
Authors: In Young Kim; You Jung Kang; Mi Jin Yoon; Eun Hee Kim; Seung U Kim; Taeg Kyu Kwon; In Ah Kim; Kyeong Sook Choi Journal: Neuro Oncol Date: 2011-02-03 Impact factor: 12.300
Authors: Julia Leitman; Boaz Barak; Ron Benyair; Marina Shenkman; Uri Ashery; F Ulrich Hartl; Gerardo Z Lederkremer Journal: PLoS One Date: 2014-03-03 Impact factor: 3.240